Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04129944
Previous Study | Return to List | Next Study

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04129944
Recruitment Status : Recruiting
First Posted : October 17, 2019
Last Update Posted : November 11, 2019
Sponsor:
Information provided by (Responsible Party):
Unity Biotechnology, Inc.

Brief Summary:
A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).

Condition or disease Intervention/treatment Phase
Osteoarthritis, Knee Drug: UBX0101 Other: Placebo Phase 2

Detailed Description:

This is a randomized, double-blind, placebo-controlled, single-dose, parallel-group study to assess the efficacy, safety, and tolerability of a single-dose intra-articular (IA) administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).

Approximately 180 patients will be randomized (1:1:1:1) to one of four treatment groups (three dose levels of UBX0101 and Placebo; approximately 45 patients per group), all administered by IA route at Week 0. The four treatment groups will be enrolled concurrently.

The primary objective of the study is to evaluate the effect of IA administration of UBX0101 on the change from baseline to Week 12 of pain in the target knee.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
Estimated Study Start Date : November 2019
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Placebo Comparator: Placebo Other: Placebo
Placebo intra-articular injection

Experimental: UBX0101 0.5 mg Drug: UBX0101
Investigational drug intra-articular injection

Experimental: UBX0101 2.0 mg Drug: UBX0101
Investigational drug intra-articular injection

Experimental: UBX0101 4.0 mg Drug: UBX0101
Investigational drug intra-articular injection




Primary Outcome Measures :
  1. Change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale (WOMAC-A) score in patients receiving a single dose of UBX0101 versus those receiving placebo [ Time Frame: Baseline to Week 12 ]
    WOMAC-A is assessed by a Likert scale on a range from 0 (none) to 4 (extreme), with higher scores indicating higher levels of pain


Secondary Outcome Measures :
  1. Change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale (WOMAC-C) score in patients receiving a single dose of UBX0101 versus those receiving placebo [ Time Frame: Baseline to Week 12 ]
    WOMAC-C is assessed by a Likert scale on a range from 0 (none) to 4 (extreme), with higher scores indicating higher levels of physical disability

  2. Change from baseline to Week 12 of the weekly mean of the average daily pain (ADP) intensity scores on the 11-point numeric rating scale (NRS) in patients receiving a single dose of UBX0101 versus those receiving placebo [ Time Frame: Baseline to Week 12 ]
    ADP is assessed by NRS on a range from 0 (no pain) to 10 (worst pain imaginable), with higher scores indicating higher levels of pain

  3. Change from baseline (over the entire 24-week period, including both the primary study period and the 12-week follow-up period) to Week 24 for the WOMAC-A, NRS, and WOMAC-C scores in patients receiving a dose of UBX0101 versus those receiving placebo [ Time Frame: Baseline to Week 24 ]
  4. Incidence of AEs as well as change from baseline through Weeks 12 and 24 in vital signs and selected laboratory safety parameters (as deemed clinically appropriate) in patients receiving a single dose of UBX0101 versus those receiving placebo [ Time Frame: Baseline to Week 24 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Patients who are ambulatory with a diagnosis of OA of the knee and who have baseline pain with a mean of ≥ 4 and ≤ 9 on the 11-point (0-10) average daily pain NRS for at least five of seven days during the Screening period.
  • Kellgren-Lawrence grade of 1-4 on a weight-bearing radiograph of target knee.
  • Patients aged ≥ 40 and ≤ 85 years.
  • Patients are permitted but not required to use an oral NSAID, serotonin and norepinephrine reuptake inhibitors (SNRIs), tramadol, or acetaminophen, provided that they have been taking a stable dose and regimen of medication for at least 4 weeks prior to Screening.

Key Exclusion Criteria:

  • Patients with any condition, including laboratory or imaging findings and findings in the medical history or in the pre-study assessments, that in the opinion of the Investigator or the Medical Monitor constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation or prevent the patient from fully participating in all aspects of the study.
  • Patients with a body mass index (BMI) ≥40 kg/m2 or a body habitus that precludes the MRI.
  • Patients with fibromyalgia
  • Systemic autoimmune disease with musculoskeletal involvement or any history of a systemic inflammatory arthritis
  • Patients who have received IA treatment in the target knee with steroids or hyaluronic acid derivatives within the last 16 weeks prior to Screening, or with extended-release corticosteroid (e.g., Zilretta®) within the last 20 weeks
  • Patients who are using a topical NSAID or topical analgesics on the target knee.
  • Patients who have used opioid analgesics (other than tramadol), marijuana or marijuana-derived products (e.g., cannabidiol), and topical capsaicin on the target knee within 8 weeks prior to Screening
  • Patients with a history of traumatic knee injury to the target knee, including, but not limited to, patients with meniscal root tear, within 2 years of study entry.
  • Patients who have undergone diagnostic arthroscopy to the target knee in the previous 6 months.
  • Patients who have undergone arthroscopic surgery (including microfracture and meniscectomy) on the target knee in the last 2 years prior to the Screening visit or are anticipated to have arthroscopic surgery on either knee at any time during the study period.
  • Patients with a history of previous total or partial knee arthroplasty.
  • Patients with an effusion at the Screening visit, which, in the opinion of the Investigator following examination and discussions with the patient, requires drainage for symptom relief.
  • Patients who have had regenerative joint procedures on any joint, including, but not limited to, platelet-rich plasma injections, stem cell transplantation, autologous chondrocyte transplantation, or mosaicplasty.
  • Patients with secondary arthritis that involves the target knee or would confound assessments of knee OA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04129944


Contacts
Layout table for location contacts
Contact: Clinical Trials at UNITY 650-416-1192 clinicaltrials@unitybiotechnology.com

Locations
Layout table for location information
United States, Alabama
Central Research Associates Recruiting
Birmingham, Alabama, United States, 35205
United States, Arizona
Tucson Orthopaedic Institute Recruiting
Tucson, Arizona, United States, 85712
United States, California
Biosolutions Clinical Research Center Recruiting
La Mesa, California, United States, 91942
United States, Florida
Well-Pharma Medical Research Recruiting
Miami, Florida, United States, 33143
Precision Clinical Research Recruiting
Sunrise, Florida, United States, 33351
United States, Kansas
The Alliance for Multispecialty Research Recruiting
Wichita, Kansas, United States, 67207
United States, Missouri
The Alliance for Multispecialty Research Recruiting
Kansas City, Missouri, United States, 64114
United States, New Jersey
Hassman Research Institute Recruiting
Berlin, New Jersey, United States, 08009
United States, New York
Rochester Clinical Research Recruiting
Rochester, New York, United States, 14609
United States, Pennsylvania
Altoona Center for Clinical Research Recruiting
Duncansville, Pennsylvania, United States, 16635
United States, South Carolina
Coastal Carolina Research Center Recruiting
North Charleston, South Carolina, United States, 29406
Sponsors and Collaborators
Unity Biotechnology, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Monitor UNITY Biotechnology

Layout table for additonal information
Responsible Party: Unity Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT04129944     History of Changes
Other Study ID Numbers: UBX0101-MUS-201
First Posted: October 17, 2019    Key Record Dates
Last Update Posted: November 11, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Unity Biotechnology, Inc.:
Osteoarthritis
Painful Osteoarthritis
Osteoarthritis, Knee
Senescence
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases